Toronto, Ontario--(Newsfile Corp. - October 22, 2021) - Awakn Life Sciences Corp. (AWKN: NEO) (AWKNF: OTCQB)('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today that Chief Executive Officer, Anthony Tennyson, will present a corporate overview at the Benzinga Global Small Cap Conference, which is being held virtually on October 27 - 28, 2021.

Mr. Tennyson will deliver his presentation on Wednesday October 27, 2021 at 11:10 a.m. ET and will be available for one-on-one meetings throughout the conference.

For more information and/or to register for the conference please visit: https://www.benzinga.com/events/small-cap/october-2021-global/

About the Benzinga Global Small Cap Conference

The Benzinga Global Small Cap Conference bridges the gap between Small Cap companies, investors, and traders. Learn about small cap investing with clearly defined educational modules, take a look at a curated group of small cap investment opportunities, and connect with the global small cap audience in an intimate, virtual setting.

About Awakn Life Sciences Corp.

Awakn Life Sciences is a biotechnology company with clinical operations, developing and delivering psychedelic therapeutics (medicines and therapies) to better treat addiction. Awakn's team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat addiction. Awakn will deliver these evidence backed psychedelic therapies in clinics in the UK and Europe and through licensing partnerships globally.